Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Oct;19(10):970-5.

Neonatal outcomes in women with gestational diabetes mellitus treated with metformin in compare with insulin: A randomized clinical trial

Safura Ruholamin  1 , Safieh Eshaghian  1 , Zahra Allame  1
Affiliations

Neonatal outcomes in women with gestational diabetes mellitus treated with metformin in compare with insulin: A randomized clinical trial

Safura Ruholamin et al. J Res Med Sci. 2014 Oct.

Abstract

Background: The objective of this study was to compare neonatal outcomes in women with gestational diabetes mellitus (GDM) treated with either metformin or insulin.

Materials and methods: A randomized clinical trial carried out on year 2011 on 109 women with GDM who did not adequately control by dietary measures. They received metformin 500 mg once or twice daily or insulin 0.2 IU/kg/day initially. The dose was titrated to achieve target blood glucose values. Neonatal outcomes such as hypoglycemia, birth weight, Apgar score, umbilical artery pH, and hyperbilirubinemia in the 50 women who remained exclusively on metformin were compared with 50 women who treated with insulin.

Results: Two groups were similar in mean fasting blood sugar (P = 0.7) and postprandial measurements (P = 0.8) throughout GDM treatment. Pregnancy complications or preterm labor were not different significantly between two groups. Considering neonatal outcomes between insulin and metformin groups, such as hypoglycemia (2 [4%] and 0 [0%], respectively), birth weight (3342 ± 506 mg and 3176 ± 438 mg, respectively), 5(th) min Apgar score <7 (no one in either group), umbilical artery pH <7.05 (no one in either group) and hyperbilirubinemia (1 [2%] and 0 [0%], respectively), no significant statistical differences were seen.

Conclusion: Based on these preliminary data, considering neonatal outcomes, metformin appears to be a safe as insulin in the treatment of GDM.

Keywords: Gestational diabetes mellitus; insulin; metformin; neonatal outcome.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest: None declared.

Figures

Figure 1
Figure 1
CONSORT statement
Figure 2
Figure 2
The average of neonatal blood sugar after 1 h postpartum in both groups
Figure 3
Figure 3
The average of neonatal blood sugar after 2 h postpartum in both groups
Figure 4
Figure 4
The average of neonatal birth weight in both groups
See this image and copyright information in PMC

References

    1. Alwan N, Tuffnell DJ, West J. Treatments for gestational diabetes. Cochrane Database Syst Rev. 2009;8:CD003395. doi:10.1002/14651858.CD003395.pub2. - PMC - PubMed
    1. Ben-Haroush A, Yogev Y, Hod M. Epidemiology of gestational diabetes mellitus and its association with type 2 diabetes. Diabet Med. 2004;21:103–13. - PubMed
    1. Soheilykhah S, Mogibian M, Rahimi-Saghand S, Rashidi M, Soheilykhah S, Piroz M. Incidence of gestational diabetes mellitus in pregnant women. Iran J Reprod Med. 2010;8:24–8.
    1. Cheung NW. The management of gestational diabetes. Vasc Health Risk Manag. 2009;5:153–64. - PMC - PubMed
    1. Lapolla A1, Dalfrà MG, Fedele D. Management of gestational diabetes mellitus. Diabetes Metab Syndr Obes. 2009;17(2):73–82. - PMC - PubMed